Pre-targeting strategies for molecular imaging and/or radioimmunotherapy
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsDexing Zeng, Lingyi Sun, Yongkang Gai
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of targeted molecular imaging and/or targeted drug delivery, wherein two components or probes each interacts with one or more biomarkers on a cell and separately interact with each other to form a stable bond, such as a stable covalent bond. In certain non-limiting embodiments, at least one of the probes is photo-triggered to allow for bonding with at least one second probe. In certain non-limiting embodiments, the cell is a tumor or cancer cell. The present invention also relates to compounds, probes, and kits for use in targeted molecular imaging and/or targeted drug delivery.
Claims12
A composition comprising:
- a. a first targeting probe comprising:
- i) an antibody or fragment thereof targeting a first cancer antigen, and
- ii) a first bioorthogonal ligation moiety;
- and
- b. a second targeting probe comprising:
- i) a peptide targeting a second cancer antigen,
- ii) a second bioorthogonal ligation moiety, and
- iii) a detectable label;
- wherein the antibody of fragment thereof is selected from the group consisting of cetuximab, pertuzumab, trastuzumab, bevacizumab, mAb 8G7, 1116NS19-9, CP-870,893, atezolizumab, UMB2, etaracizumab, and E398P
- wherein the peptide is selected from the group consisting of LLP2A, AE105, BBN(7-14), tyr(3)-octreotate, DAPTA, T140, CPCR4-2, RGD, cyclo(RGDyK), and PTP;
- wherein the first bioorthogonal ligation moiety is selected from the group consisting of trans-cyclooctene, cyclooctyne, alkyne, alkene, photo-DIBO, cyclopropenone, oxa-dibenzocyclooctyne, and dibenzocyclooctyne, and the second bioorthogonal ligation moiety is selected from the group consisting of tetrazine, azide, tetrazole, and photo-tetrazole.
A composition comprising:
- a. a first targeting probe comprising:
- i) an antibody or fragment thereof targeting a first cancer antigen, and
- ii) a first bioorthogonal ligation moiety;
- and
- b. a second targeting probe comprising:
- i) a peptide targeting a second cancer antigen,
- ii) a second bioorthogonal ligation moiety, and
- iii) optionally a detectable label;
- wherein the antibody or fragment thereof is selected from the group consisting of cetuximab, pertuzumab, trastuzumab, bevacizumab, mAb 8G7, 1116NS19-9, CP-870,893, atezolizumab, UMB2, etaracizumab, and E398P;
- wherein the peptide is selected from the group consisting of LLP2A, AE105, BBN(7-14), tyr(3)-octreotate, DAPTA, T140, CPCR4-2, RGD, cyclo(RGDyK), and PTP;
- wherein the first bioorthogonal ligation moiety is selected from the group consisting of trans-cyclooctene, cyclooctyne, alkyne, alkene, photo-DIBO, cyclopropenone, oxa-dibenzocyclooctyne, and dibenzocyclooctyne, and the second bioorthogonal ligation moiety is selected from the group consisting of tetrazine, azide, tetrazole, and photo-tetrazole.
Dependencies are inferred from the claim text.